SCHEMBL3201433

SCHEMBL3201433

Cc1ccc(C[N+]2(C)CC3C(CNC(=O)C(O)(c4ccccc4)c4ccccc4)C3C2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 2/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
PAX8 Q06710 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CCR1 P32246 1/20 0.39
CHRM2 P08172 4/20 0.38
CHRM3 P20309 4/20 0.38
ADRA1D P25100 2/20 0.38
ADRA1A P35348 2/20 0.38
ADRA1B P35368 2/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
USP2 O75604 1/20 0.37
CHRM1 P11229 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3227028 0.87 PLK4 (0.38) HTTRAB9ANPC1CCR1CHRM2
SCHEMBL3220489 0.86 CHRM2 (0.52) CHRM2CHRM3CHRM1HRH1KCNH2
SCHEMBL3210004 0.83 CHRM2 (0.41) HTTRAB9ACCR1CHRM2CHRM3
SCHEMBL3213227 0.82 CHRM2 (0.47) CHRM2CHRM3CHRM1HRH1KCNH2
SCHEMBL4131231 0.80 ALDH1A1 (0.44) SMN1; SMN2HTTRAB9ANPC1ALDH1A1
SCHEMBL4131229 0.80 ALDH1A1 (0.44) SMN1; SMN2HTTRAB9ANPC1ALDH1A1
SCHEMBL4137086 0.79 CHRM2 (0.48) SMN1; SMN2HTTRAB9ANPC1ALDH1A1
SCHEMBL4137091 0.79 CHRM2 (0.48) SMN1; SMN2HTTRAB9ANPC1ALDH1A1
SCHEMBL3213540 0.78 CHRM3 (0.46) RAB9AALDH1A1CHRM2CHRM3MEN1
SCHEMBL5099505 0.76 CHRM3 (0.45) SMN1; SMN2HTTRAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056496-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2010-03-04 US claimed
US-20100056496-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2010-03-04 US disclosed
EP-2059505-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2009-05-20 EP disclosed
WO-2008029349-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056496-A1 MUSCARINIC RECEPTOR ANTAGONISTS CHRM3, CHRM5, CHRM2 SMN1; SMN2 2082/4885HTT 3935/4885RAB9A 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.